Tower Research Capital LLC TRC Increases Position in Certara, Inc. (NASDAQ:CERT)

Tower Research Capital LLC TRC boosted its holdings in Certara, Inc. (NASDAQ:CERT - Free Report) by 473.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 27,172 shares of the company's stock after purchasing an additional 22,430 shares during the period. Tower Research Capital LLC TRC's holdings in Certara were worth $289,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the business. Venturi Wealth Management LLC raised its position in shares of Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock valued at $30,000 after purchasing an additional 2,509 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after acquiring an additional 1,047 shares during the last quarter. Blue Trust Inc. grew its holdings in Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after acquiring an additional 822 shares in the last quarter. ANTIPODES PARTNERS Ltd grew its holdings in Certara by 204.7% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock worth $58,000 after acquiring an additional 3,656 shares in the last quarter. Finally, Sterling Capital Management LLC raised its stake in shares of Certara by 57.2% in the 4th quarter. Sterling Capital Management LLC now owns 7,209 shares of the company's stock valued at $77,000 after purchasing an additional 2,624 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Stock Performance

CERT stock opened at $12.99 on Friday. The stock's fifty day moving average is $11.70 and its two-hundred day moving average is $11.65. The stock has a market capitalization of $2.10 billion, a price-to-earnings ratio of -64.95, a PEG ratio of 9.29 and a beta of 1.64. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $17.94.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Stephens reiterated an "overweight" rating and issued a $17.00 price target on shares of Certara in a research note on Thursday, February 27th. Robert W. Baird boosted their price target on Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, April 11th. KeyCorp raised their price objective on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 16th. TD Cowen started coverage on shares of Certara in a research note on Thursday, February 27th. They set a "buy" rating and a $16.00 target price for the company. Finally, Barclays reduced their price target on shares of Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $15.17.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.